iTheranostics' library of these drugs has been licensed from the University of Heidelberg in Germany. Under the terms of the deal, Novartis will develop therapeutic uses of this family of compounds, while iTheranostics will be responsible for commercializing the developed imaging agents.

Sofie may facilitate clinical supply and will be responsible for the commercialization of FAP-targeted positron emission tomography (PET) imaging tracers around the world, it said.

Preclinical lung imaging offers effective evaluation of drug candidates
Drug discovery and development are arduous and costly endeavors, with nine in 10 drug candidates failing to gain approval. Preclinical imaging can help...

Novartis secures exclusive rights to potential COVID-19 cell therapy
Novartis has entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize, and manufacture remestemcel-L...

Novartis COVID-19 mAb fails to meet clinical trial endpoints
Novartis has released new data from an interim analysis of its randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of...

Novartis acquires Vedere Bio
Novartis has acquired Vedere Bio in a deal that includes that company's lead preclinical intravitreally injected adeno-associated virus gene therapy program,...